StageZero Life Sciences

Create a vendor selection project & run comparison reports
Click to express your interest in this report
Indication of coverage against your requirements
A subscription is required to activate this feature. Contact us for more info.
Celent have reviewed this profile and believe it to be accurate.


COVID-19 Testing Is Now Available Through StageZero Life Sciences. Please view COVID-19 Testing in the Products/Services section.

Cancer is the #1 Catastrophic Claim for Employer Health Plans. Now You Can Reduce Your Catastrophic Health Claims Through StageZero Life Sciences

StageZero Life Sciences is dedicated to the early detection of cancer and multiple disease states through whole blood. Aristotle®, our next generation test, is a panel for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle is built on our proven and proprietary Sentinel Principle Technology Platform which has been validated on 10,000 patients and used to develop the first liquid biopsy for Colorectal Cancer, with further validation currently underway. In addition to building a pipeline of products for early cancer detection, the Company operates a CAP accredited and CLIA certified reference laboratory based in Richmond, Virginia that offers the ColonSentry® test as well as licensed biomarker tests for lung, breast and prostate cancers. To learn more visit

According to the CDC, Cancer will be the leading cause of death in the U.S. by 2020. More than 40% of Cancers are still diagnosed in the late stage when treatment costs are at their highest.

Benefits to Using The StageZero Employer Health Program You can Avoid the High Costs of Late Stage Cancer Treatment by:

  • Motivating non-compliant employees to participate in annual cancer screening (In office blood draws have a 95% compliance rate.)
  • Addressing gaps in current screening methods by providing additional information for clinical interventions.
  • Employers can achieve cost savings of 20% through early cancer identification & intervention.
  • Improve patient outcomes, retention, and reduce absenteeism.